Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

For the purpose of exploring the development, pharmacology and clinical trial program related to dulaglutide, we conducted a nonsystematic review of dulaglutide, focusing on the AWARD (Assessment of Weekly Administration of LY2189265 [dulaglutide] in Diabetes Assessment) program of randomized, phase...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marina V. Shestakova, Ekaterina A. Yudovich
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2017
Materias:
Acceso en línea:https://doaj.org/article/920261f7ddfc46f8917fdab419d3f48b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!